The authors have examined the effect of locally (intra-artcrially) given insulin and glucagon on the absorption and portal transport of glucose from the isolated jejunal loop of the dog. The insulin rcduccd significantly the rate of portal glucose transport, while the quantity of glucosc absorbed remained unchanged. Under the influence of glucagon the blood flow through the isolated intestinal loop and the rate of the portal glucose transport both increased. In the majority of the cases an amount of sugar exceeding the quantity of the glucose that disappeared from the lumen of the intestine appeared in the venous blood of the jejunal loop during the experimental period. On the basis of their experiments the authors suggest the ability of glucagon to mobilize glucose from the intestinal wall.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/00365521.1966.11800638 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative effectiveness of insulin glargine, glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in veterans with type 2 diabetes.
Diabetes Obes Metab
January 2025
Division of Nephrology and Hypertension, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Aims: To compare the risk of all-cause death and cardiovascular events in new users of insulin glargine, glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i), particularly in subgroups defined by baseline haemoglobin A1C (HbA1C), body mass index (BMI) and estimated glomerular filtration rate (eGFR).
Materials And Methods: We conducted an active comparator, new user design study in a national cohort of 161 405 veterans with type 2 diabetes (T2D) on metformin and initiated insulin glargine (n = 54 375), GLP-1RA (n = 22 145) or SGLT2i (n = 84 885) between 1 January 2018 and 31 December 2021. Patients were followed until 31 March 2023.
Glucagon-Like Peptide-1 Links Ingestion, Homeostasis, and the Heart.
Compr Physiol
February 2025
Physiology and Behavior Laboratory, Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland.
Glucagon-like peptide-1 (GLP-1), a hormone released from enteroendocrine cells in the distal small and large intestines in response to nutrients and other stimuli, not only controls eating and insulin release, but is also involved in drinking control as well as renal and cardiovascular functions. Moreover, GLP-1 functions as a central nervous system peptide transmitter, produced by preproglucagon (PPG) neurons in the hindbrain. Intestinal GLP-1 inhibits eating by activating vagal sensory neurons directly, via GLP-1 receptors (GLP-1Rs), but presumably also indirectly, by triggering the release of serotonin from enterochromaffin cells.
View Article and Find Full Text PDFInternational Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: Insulin and Adjunctive Treatments in Children and Adolescents with Diabetes.
Horm Res Paediatr
January 2025
Department of Pediatric Endocrinology, Rainbow Children's Hospital, Hyderabad, India.
The International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines represent a rich repository that serves as the only comprehensive set of clinical recommendations for children, adolescents, and young adults living with diabetes worldwide. This chapter builds on the 2022 ISPAD guidelines, and updates recommendations on the principles of intensive insulin regimens, including more intensive forms of multiple daily injections with new-generation faster-acting and ultra-long-acting insulins; a summary of adjunctive medications used alongside insulin treatment that includes details on pramlintide, metformin, glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RA) and sodium-glucose cotransporter inhibitors; and key considerations with regard to access to insulin and affordability to ensure that all persons with diabetes who need insulin can obtain it without financial hardship.
View Article and Find Full Text PDFGlucagon, rather than Glucagon-Like Peptide 1, Mediates Higher Post-Lunch Glucose Excursions during Breakfast Skipping in Asian Indian Patients with Uncontrolled Type 2 Diabetes Mellitus.
Indian J Endocrinol Metab
December 2024
Department of Endocrinology, Bai Yamunabai Laxman Nair Charitable Hospital and Topiwala National Medical College, Mumbai, Maharashtra, India.
Introduction: The effect and mechanism of skipping breakfast on glycemic control in type 2 diabetes mellitus (T2DM) in Asian-Indians is unknown.
Methods: Cross-over, within-group study recruiting 5 habitual breakfast eaters (BE) and 5 habitual breakfast skippers (BS) with uncontrolled T2DM (HbA1c 7-9%). Patients underwent testing after three days of following their usual breakfast habits and after seven days of crossing over to the other arm.
Shorter Digestion Times of Donor Islets Is Associated With Better Islet Graft Function After Islet Transplantation.
Cell Transplant
January 2025
Department of Translational Research & Cellular Therapeutics, Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope, Duarte, CA, USA.
Although islet transplantation is effective in reducing severe hypoglycemia events and controlling blood glucose in patients with type 1 diabetes, maintaining islet graft function long-term is a significant challenge. Islets from multiple donors are often needed to achieve insulin independence, and even then, islet function can decline over time when metabolic demand exceeds islet mass/insulin secretory capacity. We previously developed a method that calculated the islet graft function index (GFI) and a patient's predicted insulin requirement (PIR) using mathematical nonlinear regression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!